Abstract:Context: Diabetic nephropathy (DN) is a common microvascular complication in diabetic patients. The pathogenesis of DN is complex. Inflammatory response may play a key role as a common downstream pathway. Objective: The study intended to explore the relationship between the levels of plasma nucleotide-binding oligomeric domain-like receptor protein 3 (NLRP3 inflammasome), interleukin-1β (IL-1β), and IL-18 and the progression of type 2 diabetic nephropathy to clarify their relationship with type 2 diabetes mellitus (T2DM) and to provide evidence for clinical treatment. Design: The research team performed a controlled observational study. Setting: The study took place at Baoding No. 1 Central Hospital in Baoding, Hebei, China. Participants: Participants were 153 patients with T2DM who received treatment at the hospital between October 2020 and October 2021. The research team allocated 30 participants without evidence of DN to the control group. Based on the DN stage, the team assigned the 123 remaining participants to one of five observation groups: (1) 32 participants with stage 1 DN to the DN1 group, (2) 31 participants with stage 2 DN to the DN2 group, (3) 30 participants with stage 3 DN to the DN3 group, (4) 30 participants with stage 4 DN to the DN4 group, and (5) 29 participants with stage 5 DN to the DN5 group. Outcome measures: The research team measured participants' levels of "nucleotide binding oligomeric domain-like receptor protein 3" (NLRP3), interleukin-1 beta (IL-1β), and IL-18 and used the Spearman rank correlation analysis to determine the correlation between those levels and the DN stages. Results: The levels of NLRP3 , IL-1β and IL-18 in all the five observation groups were significantly higher than those in the control group (all P < .01). The levels were also significantly higher: (1) in the DN2, DN3, DN4, and DN5 groups than those in the DN1 group (all P < .01); (2) in the DN3, DN4, and DN5 groups than those in the DN2 group (all P < .01); (3) in the DN4 and DN5 groups than those in the DN3 group (all P < .01); and (4) in the DN5 groups than those in the DN4 group (all P < .01). The Spearman rank correlation analysis showed that the NLRP3, IL-1β, and IL-18 levels were significantly positively correlated with the DN stage (P = .01). Conclusions: NLRP3, IL-1β and IL-18 played an important role in the progression of T2DM, and their levels increased with the aggravation of DN. Therefore, the plasma levels of NLRP3, IL-1β and IL-18 can be useful as indicators of the occurrence and development of DN and can provide clinical guidance for the early diagnosis of DN and for the determination and adjustment of treatment plans.

Interleukin‐18 and diabetic nephropathy: A review

Deciphering interleukin-18 in diabetes and its complications: Biological features, mechanisms, and therapeutic perspectives

Correlation Between Plasma NLRP3, IL-1β, and IL-18 and Diabetic Nephropathy in Patients With Type 2 Diabetes

The role of innate immunity in diabetic nephropathy and their therapeutic consequences

Role of inflammation in diabetic nephropathy

Clinical significance of Interleukin 17 receptor E in diabetic nephropathy

Epigenetics and Inflammation in Diabetic Nephropathy

Immune responses in diabetic nephropathy: Pathogenic mechanisms and therapeutic target

Clinical Significance of Serum Interleukin‐8 and Soluble Tumor Necrosis Factor‐like Weak Inducer of Apoptosis Levels in Patients with Diabetic Nephropathy

Interleukin-18: a regulator of cancer and autoimmune diseases

Interleukin-18: recent advances

Interleukin-22 ameliorated renal injury and fibrosis in diabetic nephropathy through inhibition of NLRP3 inflammasome activation

Innate immunity in diabetic kidney disease

Inflammatory Targets in Diabetic Nephropathy

Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy

The IL-18/IL-18R1 signalling axis: Diagnostic and therapeutic potential in hypertension and chronic kidney disease

Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy

Role of Glycyrrhizin in the Reduction of Inflammation in Diabetic Kidney Disease

Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment

The relationship between B-cell lymphoma 2, interleukin-1β, interleukin-17, and interleukin-33 and the development of diabetic nephropathy

Targeting the NLRP3 Inflammasome in Diabetic Nephropathy